ZBIO vs COGT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZBIO Captures Institutional Edge (2โ1 Pillars ยท 3โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while COGT counters with relative strength in Growth & Margin. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus COGT at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against COGT sits in BREAKDOWN (5th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ZBIO Revenue | COGT Revenue | ZBIO Op. Margin | COGT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | N/A | $10M | N/A | -312.8% | COGT |
| FY2018 | N/A | $10M | N/A | -369.9% | COGT |
| FY2019 | N/A | $20M | N/A | -143.0% | COGT |
| FY2020 | N/A | $10M | N/A | -1044.3% | COGT |
| FY2023 | $50M | N/A | -74.3% | N/A | ZBIO |
| FY2024 | $10M | N/A | -3277.8% | N/A | ZBIO |
| FY2025 | $10M | N/A | -3830.6% | N/A | ZBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZBIO | COGT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $5.0B | Larger Scale | COGT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | -100.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | -2747.5% | 0.0% | Higher Margin | COGT |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -265.1% | -99.6% | Higher ROE | COGT |
| 52-Week Range Position Momentum | 46% ($14โ$45) | 1% ($27โ$44) | Stronger Trend | ZBIO |
| Beta / 30D Volatility Risk Regime | 1.16ฮฒ ยท 59% Vol | 1.46ฮฒ ยท 61% Vol | Lower Realized Risk | ZBIO |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 42.7 / 100 (HOLD) | Higher Composite | ZBIO |